“The Pink Sheet” – Most Memorable Stories Of 2006
Executive Summary
2006 was a sometimes unsettling year for the pharmaceutical industry, with companies trying to embrace, or at least survive, change - including management shake ups, major restructuring efforts and implementation of Medicare Part D. Below is a baker's dozen of the stories readers found most intriguing or informative in 2006, based on those most widely viewed in "The Pink Sheet" online.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth